Novo takes the plunge in Alzheimer’s
Novo Nordisk is pushing Rybelsus into a pivotal Alzheimer’s trial despite the failure of the Elad study.
What the coming year might hold for biopharma
Big events for 2021 include the FDA’s decision on aducanumab and pivotal readouts in diabetes and autoimmunity, while investor enthusiasm will be closely monitored.
A beautiful autumn for Covid-19 test makers
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
Boston deadheads its Lotus
Beset with problems from the off, the Lotus Edge aortic valve has finally been discontinued.
After six years Bellicum admits it’s not ready for prime time
Yet another makeover raises fresh questions over Bellicum’s technology and sees its valuation haemorrhage some more.
Veklury boosts Gilead, yet disappoints too
With Gilead's big sellers forecast to drift, investors turn to its newer projects but find little comfort.
Lilly swerves the worst case for its Covid-19 antibody
Bamlanivimab bucks could help Lilly bounce back from a soft third quarter, but diabetes is the big focus.
Bridgebio U-turn shows how money can be made twice over
The company becomes the third in two months to buy back a division it had spun out just a few years earlier.
